Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options

Rhea-AI Filing Summary

Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share, expire on May 19, 2036, and were granted as compensation.

According to the disclosure, Leff, a partner in Deerfield Management Company, L.P., has no pecuniary interest in these options and disclaims beneficial ownership, holding them for the benefit and at the direction of Deerfield Management Company, L.P. The options vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LEFF JONATHAN S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 55,150 shares (Direct, null)

Footnotes (1)

1. The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Key Figures

Options granted: 55,150 options Exercise price: $3.33 per share Expiration date: May 19, 2036 +2 more

5 metrics

Options granted 55,150 options Stock Option (Right to Buy) granted on May 19, 2026

Exercise price $3.33 per share Conversion or exercise price for granted options

Expiration date May 19, 2036 Options expire on this date if unexercised

Post-transaction derivative holdings 55,150 options Total derivative securities following this grant

Vesting date Earlier of May 19, 2027 or next annual meeting Vesting contingent on continued board service

Key Terms

Stock Option (Right to Buy), pecuniary interest, beneficial ownership, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

pecuniary interest financial

"has no pecuniary interest in the securities reported herein"

beneficial ownership financial

"disclaims beneficial ownership of such securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

vest financial

"The options vest on the earlier of (a) May 19, 2027 or (b) the date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service on the Board of Directors financial

"subject to the Reporting Person's continued service on the Board of Directors"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEFF JONATHAN S

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PENNSYLVANIA 19004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.33	05/19/2026		A		55,150(1)		(2)	05/19/2036	Common Stock	55,150(1)	$0	55,150(1)	D

Explanation of Responses:

1. The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

2. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

	/s/ Jennifer Johansson, Attorney-in-fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Larimar Therapeutics (LRMR) report for Jonathan S. Leff?

Larimar Therapeutics reported a grant of stock options covering 55,150 shares of common stock to an entity associated with director Jonathan S. Leff. These options were issued as compensation and are structured as a right to buy shares at a fixed exercise price.

What is the exercise price and expiration date of the new LRMR stock options?

The granted stock options have an exercise price of $3.33 per share and expire on May 19, 2036. This means the holder may purchase Larimar Therapeutics common shares at $3.33 any time before that expiration date, once the options are vested and exercisable.

When do the newly granted Larimar Therapeutics (LRMR) options vest?

The options vest on the earlier of May 19, 2027 or the date of Larimar Therapeutics’ next annual meeting of stockholders. Vesting in either case depends on Jonathan S. Leff’s continued service on the company’s board of directors through that vesting date.

Does Jonathan S. Leff personally benefit from the LRMR option grant?

The filing states that Jonathan S. Leff has no pecuniary interest in the reported options and disclaims beneficial ownership. He holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P., where he is a partner, rather than for his personal economic gain.

How many LRMR derivative securities does the entity hold after this option grant?

Following the transaction, the reporting line shows 55,150 derivative securities in the form of stock options. These represent rights to acquire up to 55,150 shares of Larimar Therapeutics common stock, subject to vesting terms and the stated expiration date in 2036.